ESCRS - PO0809 - Use Of Ciclosporin A 0.1% In The Management Of Ocular Surface Diseases: A District General Hospital Experience.

Use Of Ciclosporin A 0.1% In The Management Of Ocular Surface Diseases: A District General Hospital Experience.

Published 2023 - 41st Congress of the ESCRS

Reference: PO0809 | Type: Free paper | DOI: 10.82333/y530-ey80

Authors: Sze Man Vivian Lam 1 , Vivian Wing-Man Ho* 1 , Anita Lai Wah Li 1 , Tiffany Yeung 1 , Siu-Hing Wong 1 , Kenneth Kai Wang Li 1

1Ophthalmology,United Christian Hospital,Hong Kong,Hong Kong

Purpose

To report our experience of using topical cicosporin A 0.1% (Ikervis®) in the management of ocular surface disease

Setting

Retrospective study

Methods

All patients treated with Ikervis® at the United Christian Hospital, Hong Kong, between January 2020 to June 2022 were identified. Patients’ electronic medical records were reviewed. Data including patients’ demographics, indications, parameters, clinical outcomes and adverse events were collected.

Results

A total of 30 patients were identified, 27 were included and 3 patients were excluded due to lost to follow-up. Out of the 27 patients, there were 11 male and 16 female. Mean age was 51.6 +/-23. 2 and the mean follow-up was 12.9 months. Ikervis® was mainly prescribed for patients with dry eye disease (DED; 11), followed by allergic eye disease (AED; 6) and other ocular surface inflammatory disorders (OSID 10). Ocular surface disorders were stabilized in 70.4% patients. The efficacy of Ikervis® was highest in DED (9) and treatment persisted successfully in 70.4% of patients. Eight patients discontinued Ikervis®. There were no significant differences in treatment efficiency (p= 0.5163) and frequency for the different diagnoses (p=0.134).

Conclusions

Our cohort suggests that Ikervis® was effective and well tolerated in majority of patients in the treatment of DED and OSID.